Patents Assigned to ZymoGenetics, Inc.
  • Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
    Patent number: 8808696
    Abstract: The present invention provides methods and compositions for treatment of hyperproliferative disorders and cancers, including multiple myeloma and Waldenström's macroglobulinemia, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: August 19, 2014
    Assignees: Ares Trading S.A., Zymogenetics, Inc.
    Inventors: Herve Broly, Arnaud Ythier, Eric Sievers
  • LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS
    Publication number: 20140220014
    Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 7, 2014
    Applicants: University of Washington, ZymoGenetics, Inc.
    Inventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon
  • Methods for treating disease using an anti-IL-21 receptor antibody
    Patent number: 8790643
    Abstract: Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2R?; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: July 29, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Pallavur V. Sivakumar, Stephen R. Jaspers
  • Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
    Patent number: 8784812
    Abstract: In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: July 22, 2014
    Assignees: Zymogenetics, Inc., Ares Trading S.A.
    Inventors: Herve Broly, Jennifer Visich, Ivan Nestorov, Sharon Busby, Jane Gross
  • Method of treating atopic dermatitis with antibody to zcytor17 ligand
    Patent number: 8778344
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: July 15, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond
  • POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20140186891
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 3, 2014
    Applicants: Merck Serono S/A, ZymoGenetics, Inc.
    Inventors: Kent BONDENSGAARD, Roland Beckmann
  • METHODS OF TREATING PAIN USING AN IL-31RA OR OSMR-B ANTAGONIST
    Publication number: 20140186346
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 3, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Yue YAO, Janine Bilsborough
  • HOMOGENOUS PREPARATIONS OF IL-28 AND IL-29
    Publication number: 20140178333
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Application
    Filed: January 28, 2014
    Publication date: June 26, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Thrombin activator compositions and methods of making and using the same
    Patent number: 8759066
    Abstract: Disclosed are compositions for activating thrombin precursors to thrombin. The compositions provided include polypeptide compositions wherein the pre-pro-sequence comprises a thrombin cleavage site. The compositions provided also include polynucleotides encoding said polypeptides and recombinant systems for expressing said polypeptides. This disclosure also relates to methods for producing said compositions, recovering said compositions, activating said compositions purifying said compositions and producing active thrombin molecules using the active form of said compositions.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: June 24, 2014
    Assignee: Zymogenetics, Inc.
    Inventors: Paul D. Bishop, Tracey A. Pownder, Paul O. Sheppard, Christopher J. Stenland
  • Production and purification of IL-29
    Patent number: 8759027
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 24, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Geoffrey F. Lee, Robert M. Dedinsky
  • Mutants of IL-29
    Patent number: 8734776
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: May 27, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR
    Publication number: 20140141485
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: December 23, 2013
    Publication date: May 22, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Method of treating rheumatoid arthritis using anti-IL-20 antibodies
    Patent number: 8728469
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: May 20, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
  • SOLUBLE HYBRID FCGAMMA RECEPTORS AND RELATED METHODS
    Publication number: 20140107034
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Application
    Filed: December 17, 2013
    Publication date: April 17, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Carl W. BIRKS, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
  • Nucleic acid molecules encoding humanized antibody molecules specific for IL-31
    Patent number: 8685669
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: April 1, 2014
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Methods of antagonizing signal transduction in dorsal root ganglion cells
    Patent number: 8685395
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: April 1, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20140080181
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Application
    Filed: September 19, 2013
    Publication date: March 20, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Soluble hybrid Fc? receptors and related methods
    Patent number: 8658766
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: February 25, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Carl W. Birks, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
  • USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS
    Publication number: 20140044676
    Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 13, 2014
    Applicant: ZymoGenetics, Inc.
    Inventor: Paul O. Sheppard
  • Polynucleotides encoding antibodies to cytokine receptor zcytor17
    Patent number: 8648182
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: February 11, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer